Originally posted by Dazaau
While it was a simplification of the facts, on the other side we have to remember there is no guarantee anything will be sold, let alone cash received, this quarter.
For example:
Around 1 year ago an infusion deal was imminent. Still waiting
TGA approval was expected two quarters ago. Still waitng.
Europe approval... still waiting.
TAVR update.....
So, while it is possible that this quarter will be a ripper with a TAVR update, infusion sale, immunotherapy deal, TGA approval, Europe etc. It is also possible it will be like last quarter. Radio silence. I am a little concerned that there appears a deliberate shift to avoid announcing anything, the company has gone from announcing every little thing they could to reporting as little as humanly possible.
Who knows anymore. These levels are certainly cheap. Worth a punt for some I'm sure.
Hi Daz, imo, in regards to prospects for Admedus, in the immediate future, it will be dependent on; TAVR update, infusion sale, immunotherapy deal, TGA approval etc l IN the next quarter, as far as current shareholders are concerned, more so for LT holders.
Of the four potential updates what will be the minimum to keep this alive? (as in sp appreciation And more importantly POSTIVE sentiment), what is needed and how much in funds, to stave off a further CR?, at this current sp a future CR will see this company virtually be handed over to SB/SIO.
I have no problem with that although AT A FAIR PREMIUM to current sp, whats fair?, guess that is in the eye of the beholder!
Postive announcements, again imo, should create enough postive sentiment to counter lags in revenue IF coupled up with reduced cash burn.
Absolutely a game of attrition, IF all the above announcements imminent then it is vital to current shareholders that it happens in the immediate future, delay will go against current shareholders and deliver the company SB/SIO in the long run.
For reflection, SB at one end and SIO at the other end, ‘book end’ cornerstone investors, in theory beneficial to retail holders or not?, in theory yes.
For further reflection, why in the heck would Admedus invest 18 mill in immunotheries division, (from sale of interests) for their contribution to R&D, with no guarantees of success, when 18 mill would be the equivalent of, perhaps, TWO CRs?
Would SB pay that outright OR not?, bearing in mind current Market value of company.
18 mill in hand PLUS retaining interest of 1 or 2 per cent interest IF vac successful would be a solid outcome, imo.
Atten; @cromulet, don’t see you as either offensive or a down ramper, imo, nice to see some original concepts, too many journey persons along the way have lost significant amounts of money and ‘left the building’, doesn’t mean their contributions are valueless.
(20min delay)